CytoAgents looks forward to a big 2021 and beyond

CytoAgents looks forward to a big 2021 and beyond

Up next are two clinical trials, a phase-two clinical trial for GP1681 in the area of Covid-19 and a separate clinical that will determine how it works with CAR-T patients. It’s shaping up to be a busy year for Pittsburgh-based CytoAgents, an early stage pharmaceutical company based in Pittsburgh whose drug candidate. Read more >>

Share this post